Consolidated balance sheet as at December 31
in CHF 1 000 | Notes | 2024 | 2023 | |||
Current assets | ||||||
Cash and cash equivalents | 458 | 501 | ||||
Receivables from brokers | – | 1 829 | ||||
Securities | 2 406 881 | 2 634 714 | ||||
Other assets | 60 | 110 | ||||
2 407 399 | 2 637 154 | |||||
Total assets | 2 407 399 | 2 637 154 | ||||
Current liabilities | ||||||
Short-term borrowings from banks | 117 500 | 304 900 | ||||
Payables to brokers | – | 5 436 | ||||
Other short-term liabilities | 3 513 | 3 491 | ||||
Tax liabilities | 94 | 110 | ||||
121 107 | 313 937 | |||||
Total liabilities | 121 107 | 313 937 | ||||
Shareholders' equity | ||||||
Share capital | 11 080 | 11 080 | ||||
Treasury shares | (39 640) | (36 508) | ||||
Retained earnings | 2 314 852 | 2 348 645 | ||||
2 286 292 | 2 323 217 | |||||
Total liabilities and shareholders' equity | 2 407 399 | 2 637 154 | ||||
Net asset value per share in CHF | 41.75 | 42.35 |
The notes are an integral part of the consolidated financial statements.
The consolidated financial statements were approved by the Board of Directors of BB Biotech AG on February 18, 2025.